Reproductive Medicine Associates Of New Jersey Releases 2011 IVF Success Rates

Achieved Live Birth or Delivery Rates of 64.4% in Women Under 35 -- 24% Higher Than the National Average

Feb 11, 2013, 09:00 ET from Reproductive Medicine Associates of New Jersey

BASKING RIDGE, N.J., Feb. 11, 2013 /PRNewswire/ -- Reproductive Medicine Associates of New Jersey (RMANJ) has released in vitro fertilization (IVF) success rates for the year ending December 2011, showing a marked increase in successful pregnancies and live births per cycle initiated.  RMANJ, a world-renowned leader in the field of Assisted Reproductive Technology (ART), credits the continued increase in successful pregnancies to their pioneering research in the areas of blastocyst embryo transfer, SelectCCS (Comprehensive Chromosome Screening), trophectoderm biopsy (TE) of embryos for genetic testing, and Single Embryo Transfer (SET).

(Logo: )

The 2011 data is based on pregnancy and delivery rates of nearly 2,000 treatment cycles across all age groups.  Information is governed by The Society of Assisted Reproductive Technology (SART), the primary organization of professionals dedicated to the practice of Assisted Reproductive Technologies in the United States. RMANJ's full Clinic Summary Report can be viewed at

RMANJ continues to outpace the nation with this latest data showing a live birth rate per cycle initiated of 64.4% in women under 35 years of age. The average number of embryos transferred in this age group was 1.8.

SART Pregnancy Success Rates in Women Under 35 Years

Fresh Embryo Cycles (non-donor eggs)



Percent of embryos transferred resulting in implantation



Percent of cycles resulting in pregnancies



Percent of cycles resulting in deliveries



Percent of cancellations



Average number of embryos transferred



Please note: A comparison of clinic success rates may not be meaningful because a patient's medical characteristics, treatment approaches and entrance criteria for ART may vary from clinic to clinic.

Dr. Richard T. Scott, founding partner of RMANJ, says advancements like SelectCCS enable RMANJ physicians to transfer only the most viable embryo, increasing the likelihood of implantation and healthy delivery.

"Published data suggests that 50-70% of miscarriages are due to embryos with too few or too many chromosomes.  At RMANJ, we've developed a one-of-a-kind, rapid 24-chromosome screening platform that can identify which embryos are euploid, or have the correct number of chromosomes," he says. "Using this approach, we can then transfer only one healthy embryo if the patient chooses, eliminating the risk of multiple pregnancies and births, the most common and costly complication of IVF, while maintaining high success rates."

Other centers have attempted similar embryo testing methods, but RMANJ is the only fertility center in the world to have developed a system of unprecedented accuracy, fully validated through years of rigorous clinical research, including the recent BEST (Blastocyst Euploid Selective Transfer) clinical trial. Further advancing RMANJ's technique is its laboratory's distinction as an exclusive blastocyst-transfer program, capable of allowing embryos to develop for five to six days prior to transfer.

"More time in the lab enables embryos the opportunity to amass higher numbers of cells, making them more viable for the embryo selection process and less susceptible to complications following testing," Dr. Scott says.  "With accuracy rates up to 98%1,2, SelectCCS  is helping to redefine success in IVF."

RMANJ's commitment to stay at the forefront of pioneering reproductive medicine is based in the belief that continuous improvement is the key to enabling more patients to become parents.

"We have a singular goal of developing tomorrow's technology today, to shape the future of our field," says Dr. Thomas Molinaro from RMANJ's Eatontown, NJ office. "This commitment easily translates into better outcomes for our patients."

Dr. Shefali Mavani Shastri, who practices out of several of RMANJ's offices including the Overlook Medical Center in Summit, says her patients truly benefit from the center's uparalleled commitment to excellence, from the state of the art embryology laboratory to the exceptional clinical care.  We strive to offer our patients the most cutting edge treatment in a compassionate, personalized setting.

"Through our novel research and breakthrough technologies, we are redefining the way fertility medicine is being practiced today, with a focus on achieving the highest pregnancy rates and ensuring the safest pregnancies possible for our patients."   

About SART
The Society for Assisted Reproductive Technology, or SART, is the primary organization of professionals dedicated to the practice of assisted reproductive technologies (ART) in the United States.  SART includes more than 375 member practices, representing more than 85 percent of the ART clinics in our country.  The mission of the organization is to set and help maintain the standards for ART in an effort to better serve its members and patients.  One of the most important functions of the SART website is to help patients locate and contact infertility clinics and view national and individual clinic IVF success rates

Please note, a comparison of clinic success rates may not be meaningful because a patient's medical characteristics, treatment approaches and entrance criteria for ART may vary from clinic to clinic.

About Reproductive Medicine Associates of New Jersey
The fertility experts at RMANJ have among the highest IVF success rates in the country, and consistently report pregnancy success rates above the regional and national average. The world-renowned RMANJ laboratory in Basking Ridge has been recognized by both competitors in the field and scientific institutions as a standard of excellence. Since 1999, they have helped bring nearly 30,000 babies to loving families.  In addition to serving as the Division of Reproductive Endocrinology at Robert Wood Johnson University Medical School in New Brunswick, NJ, the practice has seven locations in New Jersey. For more information please call RMANJ at 973-656-2089, or visit

1. Treff N, Su J, Tao X, Miller K, Scott RT Jr. First IVF babies born after rapid 24 chromosome embryo aneuploidy screening and fresh embryo transfer. Fertil Steril 2009a;92:S49.

2. Treff NR, Su J, Tao X, Miller KA, Levy B, Scott RT Jr. A novel single-cell DNA fingerprinting method successfully distinguishes sibling human embryos. Fertil Steril 2009b;94:477–484.

SOURCE Reproductive Medicine Associates of New Jersey